secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001683168-24-004417
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio shareholders approve reverse stock split (1:2-1:9) and 500K share increase to LTIP
--------------------------------------------------------------------------------

- Reverse stock split proposal approved with 1,879,666 For, 313,572 Against; board to set exact ratio and effective date.
- Amendment to 2020 Long Term Incentive Plan approved, increasing shares by 500,000 to total 725,500.
- All five director nominees elected: Bitterman, Bradford, Ferrara, Freeman, Lockshin, each with >559K For votes.
- Ratification of BDO USA as independent auditor for FY 2024 approved with 2,075,307 For votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004417/0001683168-24-004417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824004417/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-004417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer